Treatment  ||| S:0 E:10 ||| NN
of  ||| S:10 E:13 ||| IN
rheumatoid  ||| S:13 E:24 ||| JJ
arthritis  ||| S:24 E:34 ||| NN
and  ||| S:34 E:38 ||| CC
ankylosing  ||| S:38 E:49 ||| NNS
spondylitis  ||| S:49 E:61 ||| VBP
The  ||| S:61 E:65 ||| DT
treatment  ||| S:65 E:75 ||| NN
of  ||| S:75 E:78 ||| IN
the  ||| S:78 E:82 ||| DT
two  ||| S:82 E:86 ||| CD
most  ||| S:86 E:91 ||| RBS
frequent  ||| S:91 E:100 ||| JJ
inflammatory  ||| S:100 E:113 ||| FW
rheumatic  ||| S:113 E:123 ||| FW
diseases  ||| S:123 E:132 ||| FW
rheumatoid  ||| S:132 E:143 ||| FW
arthritis  ||| S:143 E:153 ||| FW
( ||| S:153 E:154 ||| -LRB-
RA ||| S:154 E:156 ||| NNP
)  ||| S:156 E:158 ||| -RRB-
and  ||| S:158 E:162 ||| CC
ankylosing  ||| S:162 E:173 ||| JJ
spondylitis  ||| S:173 E:185 ||| NNS
( ||| S:185 E:186 ||| -LRB-
AS ||| S:186 E:188 ||| NNP
)  ||| S:188 E:190 ||| -RRB-
has  ||| S:190 E:194 ||| VBZ
some  ||| S:194 E:199 ||| DT
similarities  ||| S:199 E:212 ||| NNS
but  ||| S:212 E:216 ||| CC
in  ||| S:216 E:219 ||| IN
total  ||| S:219 E:225 ||| JJ
more  ||| S:225 E:230 ||| JJR
differences ||| S:230 E:241 ||| NNS
.  ||| S:241 E:243 ||| .
Thus ||| S:243 E:247 ||| RB
,  ||| S:247 E:249 ||| ,
therapy  ||| S:249 E:257 ||| NN
with  ||| S:257 E:262 ||| IN
non-steroidal  ||| S:262 E:276 ||| JJ
anti-inflammatory  ||| S:276 E:294 ||| JJ
agents  ||| S:294 E:301 ||| NNS
( ||| S:301 E:302 ||| -LRB-
NSAIDs ||| S:302 E:308 ||| NNP
) ||| S:308 E:309 ||| -RRB-
,  ||| S:309 E:311 ||| ,
conventional  ||| S:311 E:324 ||| JJ
disease  ||| S:324 E:332 ||| NN
modifying  ||| S:332 E:342 ||| VBZ
anti-rheumatic  ||| S:342 E:357 ||| JJ
drugs  ||| S:357 E:363 ||| NNS
( ||| S:363 E:364 ||| -LRB-
DMARDs ||| S:364 E:370 ||| NNP
)  ||| S:370 E:372 ||| -RRB-
and  ||| S:372 E:376 ||| CC
biologic  ||| S:376 E:385 ||| JJ
agents  ||| S:385 E:392 ||| NNS
has  ||| S:392 E:396 ||| VBZ
a  ||| S:396 E:398 ||| DT
different  ||| S:398 E:408 ||| JJ
role  ||| S:408 E:413 ||| NN
in  ||| S:413 E:416 ||| IN
the  ||| S:416 E:420 ||| DT
management  ||| S:420 E:431 ||| NN
and  ||| S:431 E:435 ||| CC
different  ||| S:435 E:445 ||| JJ
efficacy  ||| S:445 E:454 ||| NN
in  ||| S:454 E:457 ||| IN
AS  ||| S:457 E:460 ||| NNP
and  ||| S:460 E:464 ||| CC
RA ||| S:464 E:466 ||| NNP
.  ||| S:466 E:468 ||| .
This  ||| S:468 E:473 ||| DT
implies  ||| S:473 E:481 ||| JJ
signs  ||| S:481 E:487 ||| NNS
and  ||| S:487 E:491 ||| CC
symptoms ||| S:491 E:499 ||| NNS
,  ||| S:499 E:501 ||| ,
function ||| S:501 E:509 ||| NN
,  ||| S:509 E:511 ||| ,
and  ||| S:511 E:515 ||| CC
structural  ||| S:515 E:526 ||| JJ
damage ||| S:526 E:532 ||| NN
.  ||| S:532 E:534 ||| .
This  ||| S:534 E:539 ||| DT
is  ||| S:539 E:542 ||| VBZ
in  ||| S:542 E:545 ||| IN
part  ||| S:545 E:550 ||| NN
due  ||| S:550 E:554 ||| JJ
to  ||| S:554 E:557 ||| TO
the  ||| S:557 E:561 ||| DT
different  ||| S:561 E:571 ||| JJ
pathogenesis ||| S:571 E:583 ||| NN
:  ||| S:583 E:585 ||| :
( ||| S:585 E:586 ||| -LRB-
i ||| S:586 E:587 ||| FW
)  ||| S:587 E:589 ||| -RRB-
while  ||| S:589 E:595 ||| IN
the  ||| S:595 E:599 ||| DT
synovium  ||| S:599 E:608 ||| NN
is  ||| S:608 E:611 ||| VBZ
an  ||| S:611 E:614 ||| DT
important  ||| S:614 E:624 ||| JJ
target  ||| S:624 E:631 ||| NN
in  ||| S:631 E:634 ||| IN
RA  ||| S:634 E:637 ||| NNP
it  ||| S:637 E:640 ||| PRP
is  ||| S:640 E:643 ||| VBZ
rather  ||| S:643 E:650 ||| RB
the  ||| S:650 E:654 ||| DT
bone  ||| S:654 E:659 ||| NN
in  ||| S:659 E:662 ||| IN
AS  ||| S:662 E:665 ||| NNP
and  ||| S:665 E:669 ||| CC
( ||| S:669 E:670 ||| -LRB-
ii ||| S:670 E:672 ||| LS
)  ||| S:672 E:674 ||| -RRB-
while  ||| S:674 E:680 ||| IN
the  ||| S:680 E:684 ||| DT
pathology  ||| S:684 E:694 ||| NN
in  ||| S:694 E:697 ||| IN
RA  ||| S:697 E:700 ||| NNP
is  ||| S:700 E:703 ||| VBZ
rather  ||| S:703 E:710 ||| RB
osteodestructive  ||| S:710 E:727 ||| VBN
to  ||| S:727 E:730 ||| TO
cartilage  ||| S:730 E:740 ||| VB
and  ||| S:740 E:744 ||| CC
bone  ||| S:744 E:749 ||| NN
presenting  ||| S:749 E:760 ||| NN
with  ||| S:760 E:765 ||| IN
erosions ||| S:765 E:773 ||| NN
,  ||| S:773 E:775 ||| ,
it  ||| S:775 E:778 ||| PRP
is  ||| S:778 E:781 ||| VBZ
predominantly  ||| S:781 E:795 ||| RB
osteoproliferative  ||| S:795 E:814 ||| VBN
in  ||| S:814 E:817 ||| IN
AS  ||| S:817 E:820 ||| NNP
as  ||| S:820 E:823 ||| RB
indicated  ||| S:823 E:833 ||| VBN
by  ||| S:833 E:836 ||| IN
syndesmophytes  ||| S:836 E:851 ||| NN
and  ||| S:851 E:855 ||| CC
ankylosis ||| S:855 E:864 ||| NN
.  ||| S:864 E:866 ||| .
Biologic  ||| S:866 E:875 ||| JJ
agents  ||| S:875 E:882 ||| NNS
targeting  ||| S:882 E:892 ||| VBG
tumor  ||| S:892 E:898 ||| NN
necrosis  ||| S:898 E:907 ||| NN
factor  ||| S:907 E:914 ||| NN
( ||| S:914 E:915 ||| -LRB-
TNF-alpha ||| S:915 E:924 ||| NNP
)  ||| S:924 E:926 ||| -RRB-
work  ||| S:926 E:931 ||| VBP
clinically  ||| S:931 E:942 ||| RB
well  ||| S:942 E:947 ||| RB
in  ||| S:947 E:950 ||| IN
both  ||| S:950 E:955 ||| DT
diseases  ||| S:955 E:964 ||| NNS
but ||| S:964 E:967 ||| CC
,  ||| S:967 E:969 ||| ,
while  ||| S:969 E:975 ||| IN
they  ||| S:975 E:980 ||| PRP
clearly  ||| S:980 E:988 ||| RB
inhibit  ||| S:988 E:996 ||| VB
structural  ||| S:996 E:1007 ||| JJ
damage  ||| S:1007 E:1014 ||| NN
in  ||| S:1014 E:1017 ||| IN
RA ||| S:1017 E:1019 ||| NNP
,  ||| S:1019 E:1021 ||| ,
they  ||| S:1021 E:1026 ||| PRP
do  ||| S:1026 E:1029 ||| VBP
not  ||| S:1029 E:1033 ||| RB
seem  ||| S:1033 E:1038 ||| VB
to  ||| S:1038 E:1041 ||| TO
have  ||| S:1041 E:1046 ||| VB
much  ||| S:1046 E:1051 ||| JJ
influence  ||| S:1051 E:1061 ||| NN
on  ||| S:1061 E:1064 ||| IN
new  ||| S:1064 E:1068 ||| JJ
bone  ||| S:1068 E:1073 ||| NN
formation  ||| S:1073 E:1083 ||| NN
in  ||| S:1083 E:1086 ||| IN
AS ||| S:1086 E:1088 ||| NNP
.  ||| S:1088 E:1090 ||| .
DMARDs  ||| S:1090 E:1097 ||| NNS
are  ||| S:1097 E:1101 ||| VBP
efficacious  ||| S:1101 E:1113 ||| VBN
in  ||| S:1113 E:1116 ||| IN
RA  ||| S:1116 E:1119 ||| NNP
but  ||| S:1119 E:1123 ||| CC
less  ||| S:1123 E:1128 ||| RBR
so  ||| S:1128 E:1131 ||| RB
in  ||| S:1131 E:1134 ||| IN
AS ||| S:1134 E:1136 ||| NNP
.  ||| S:1136 E:1138 ||| .
NSAIDs  ||| S:1138 E:1145 ||| NNS
are  ||| S:1145 E:1149 ||| VBP
efficacious  ||| S:1149 E:1161 ||| VBN
in  ||| S:1161 E:1164 ||| IN
both  ||| S:1164 E:1169 ||| DT
RA  ||| S:1169 E:1172 ||| NNP
and  ||| S:1172 E:1176 ||| CC
AS ||| S:1176 E:1178 ||| NNP
,  ||| S:1178 E:1180 ||| ,
but  ||| S:1180 E:1184 ||| CC
they  ||| S:1184 E:1189 ||| PRP
are  ||| S:1189 E:1193 ||| VBP
considered  ||| S:1193 E:1204 ||| VBN
first  ||| S:1204 E:1210 ||| JJ
line  ||| S:1210 E:1215 ||| NN
of  ||| S:1215 E:1218 ||| IN
therapy  ||| S:1218 E:1226 ||| NN
in  ||| S:1226 E:1229 ||| IN
AS  ||| S:1229 E:1232 ||| NNP
while  ||| S:1232 E:1238 ||| IN
they  ||| S:1238 E:1243 ||| PRP
are  ||| S:1243 E:1247 ||| VBP
rather  ||| S:1247 E:1254 ||| RB
adjunctive  ||| S:1254 E:1265 ||| JJ
agents  ||| S:1265 E:1272 ||| NNS
in  ||| S:1272 E:1275 ||| IN
RA ||| S:1275 E:1277 ||| NNP
.  ||| S:1277 E:1279 ||| .
In  ||| S:1279 E:1282 ||| IN
AS ||| S:1282 E:1284 ||| NNP
,  ||| S:1284 E:1286 ||| ,
NSAIDs ||| S:1286 E:1292 ||| NNP
,  ||| S:1292 E:1294 ||| ,
potentially  ||| S:1294 E:1306 ||| RB
especially  ||| S:1306 E:1317 ||| RB
coxibs ||| S:1317 E:1323 ||| JJ
,  ||| S:1323 E:1325 ||| ,
may  ||| S:1325 E:1329 ||| MD
even  ||| S:1329 E:1334 ||| RB
prevent  ||| S:1334 E:1342 ||| VB
new  ||| S:1342 E:1346 ||| JJ
bone  ||| S:1346 E:1351 ||| NN
formation  ||| S:1351 E:1361 ||| NN
due  ||| S:1361 E:1365 ||| JJ
to  ||| S:1365 E:1368 ||| TO
their  ||| S:1368 E:1374 ||| PRP$
inhibitory  ||| S:1374 E:1385 ||| JJ
effect  ||| S:1385 E:1392 ||| NN
on  ||| S:1392 E:1395 ||| IN
cyclooxygenase-2 ||| S:1395 E:1411 ||| CD
.  ||| S:1411 E:1413 ||| .
